MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha

Oncogene

Volumn 33, Issue 3, 2014, Pages 387-397

  Zhang, H ^a   Pu, J ^a   Qi, T ^a   Qi, M ^a   Yang, C ^a   Li, S ^a   Huang, K ^a   Zheng, L ^a   Tong, Q ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

hypoxia inducible factor 2 alpha; microRNA 145; neuroblastoma

Indexed keywords

CYCLIN D1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LUCIFERASE; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; MICRORNA 145; VASCULOTROPIN;

3' UNTRANSLATED REGION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER INHIBITION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MALE; METASTASIS; MOUSE; MUTATION; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; CHILD, PRESCHOOL; CYCLIN D1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INFANT; MALE; MATRIX METALLOPROTEINASE 14; MICE; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892671741     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.574     Document Type: Article

References (40)

1. Ara T, DeClerck Y. Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Rev 2006; 25: 645-657.
2. Holmquist-Mengelbier L, Fredlund E, Lö fstedt T, Noguera R, Navarro S, Nilsson H et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006; 10: 413-423.
3. Stallings RL. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des 2009; 15: 456-462.
4. Wei JS, Song YK, Durinck S, Chen QR, Cheuk ATC, Tsang P et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008; 27: 5204-5213.
5. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, Buckley PG et al. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 2010; 9: 83.
6. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008; 3: e2236.
7. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401-1414.
8. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882-891.
9. Chiyomaru T, Tatarano S, Kawakami K, Enokida H, Yoshino H, Nohata N et al. SWAP70, actin-binding protein, function as an oncogene targeting tumorsuppressive miR-145 in prostate cancer. Prostate (e-pub ahead of print 25 February 2011; doi:10.1002/pros.21372).
10. Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009; 34: 1461-1466.
11. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010; 127: 2804-2814.
12. Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 2011; 13: 1090-1098.
13. Koo S, Martin G, Schulz K, Ronck M, Toussaint L. Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines. BMC Cancer 2012; 12: 143.
14. Zheng LD, Tong QS, Tang ST, Du ZY, Liu Y, Jiang GS et al. Expression and clinical significance of heparanase in neuroblastoma. World J Pediatr 2009; 5: 206-210.
15. Baba M, Hirai S, Yamada-Okabe H, Kenji H, Tabuchi H, Kobayashi K et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor. Oncogene 2003; 22: 2728-2738.
16. Petrella BL, Lohi J, Brinckerhoff CE. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 2004; 24: 1043-1052.
17. Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, Li JL et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindauassociated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675-5686.
18. Covello KL, Simon MC, Keith B. Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res 2005; 65: 2277-2286.
19. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R. MicroRNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007; 282: 32582-32590.
20. Zhang J, Guo H, Zhang H, Wang H, Qian G, Fan X et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene friend leukemia virus integration 1 gene. Cancer 2011; 117: 86-95.
21. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106: 3207-3212.
22. Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 2012; 11: 2137-2145.
23. Gö tte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010; 29: 6569-6580.
24. Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C et al. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 2013; 32: 491-501.
25. Speranza MC, Frattini V, Pisati F, Kapetis D, Porrati P, Eoli M et al. NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget 2012; 3: 723-734.
26. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012; 40: 761-774.
27. Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjö lund J, Gisselsson D et al. HIF-2 alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106: 16805-16810.
28. Cha ST, Chen PS, Johansson G, Chu CY, Wang MY, Jeng YM et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res 2010; 70: 2675-2685.
29. Lei Z, Li B, Yang Z, Fang H, Zhang GM, Feng ZH et al. Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PLoS One 2009; 4: e7629.
30. Acker T, ez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L et al. Genetic evidence for a tumor suppressor role of HIF-2 alpha. Cancer Cell 2005; 8: 131-141.
31. Poincloux R, Lizárraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci 2009; 122: 3015-3024.
32. Aplin AC, Zhu WH, Fogel E, Nicosia RF. Vascular regression and survival are differentially regulated by MT1-MMP and TIMPs in the aortic ring model of angiogenesis. Am J Physiol Cell Physiol 2009; 297: C471-C480.
33. Liu H, Kohane IS. Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy. PLoS One 2009; 4: e5436.
34. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009; 9: 374.
35. Borel C, Antonarakis SE. Functional genetic variation of human miRNAs and phenotypic consequences. Mamm Genome 2008; 19: 503-509.
36. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M et al. Singlenucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res 2010; 70: 2789-2798.
37. Zheng L, Jiang G, Mei H, Pu J, Dong J, Hou X et al. Small RNA interferencemediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells. BMC Cancer 2010; 10: 33.
38. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by 'walking' the genes of three genomes. J Biomed Inform 2011; 44: 839-847.
39. Chae KS, Kang MJ, Lee JH, Ryu BK, Lee MG, Her NG et al. Opposite functions of HIF-a isoforms in VEGF induction by TGF-b1 under non-hypoxic conditions. Oncogene 2011; 30: 1213-1228.
40. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D et al. miR-9, a MYC/MYCNactivated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.